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A comparison of transplant outcomes in peritoneal and hemo- The role of pre-transplant dialysis modality in affect-
dialysis patients. ing transplant outcomes has been the subject of long-
Background. Studies examining the effect of pre-transplant standing interest. Recent studies have reported that peri-dialysis modality on graft and patient survival after kidney
toneal dialysis is associated with a lower incidence oftransplantation have produced conflicting results. Therefore,
post-transplant delayed graft function (DGF) comparedwe studied the effects of pre-transplant dialysis modality on
outcomes in a large United States cohort. to hemodialysis [1–5]. On the other hand, there have
Methods. We compared rates of transplantation between been reports that patients receiving peritoneal dialysis
peritoneal dialysis and hemodialysis patients from the years are more likely to have graft thrombosis compared to1995 to 1998 in the United States (N  252,402) and outcomes
patients treated with hemodialysis [6–9]. Most previousafter transplantation (N 22,776), using data from the Centers
studies have reported that graft survival is not affectedfor Medicare and Medicaid Services.
Results. In a Cox proportional hazards analysis that was ad- by the modality of dialysis treatment prior to transplanta-
justed for multiple patient characteristics, kidney transplantation tion [2, 9–14]. However, many of these studies were
was 1.39 (95% CI 1.35 to 1.43) times more likely in peritoneal
small, had a limited number of factors that were ad-dialysis vs. hemodialysis patients (P 0.0001). Over the entire
dressed in the analysis and may have lacked adequatefollow-up period, the adjusted risk for death-censored graft
failure was 1.15 (1.04 to 1.26) times higher in peritoneal dialysis statistical power to determine whether dialysis treatment
vs. hemodialysis (P  0.05), but mortality and overall graft modality is independently associated with graft survival.
failure rates were not different. Pre-transplant dialysis modality Fundamental to assessing the relationship between di-did not affect outcomes for patients who survived with a func-
alysis modality and post-transplant outcomes is the likeli-tioning kidney for at least 3 months. However, in adjusted Cox
hood of receiving a renal transplant based on the choiceanalyses restricted to the first 3 months, peritoneal dialysis was
associated with a 1.23 (1.09 to 1.39) times higher risk for early of peritoneal dialysis or hemodialysis as the initial treat-
graft failure (P  0.001) and a 1.33 (1.16 to 1.53) times higher ment for end-stage renal disease (ESRD). Since the num-
risk for death-censored graft failure (P  0.001). Peritoneal
ber of factors that may be associated with the transplantdialysis patients, however, were seen to have a lower incidence
process are considerable, we chose to study a large cohortof delayed graft function. In a smaller sample of patients with
data on causes of early graft failure, graft thrombosis was more of United States ESRD patients with information not
commonly listed as a cause of graft failure among peritoneal only on their dialysis treatment period but also their
dialysis patients, 41% (64/156), compared to hemodialysis pa- profile of transplant donor and recipient characteristics.
tients, 30% (106/349), P  0.05.
This report summarizes our finding from data suppliedConclusions. Kidney transplantation is more frequent in peri-
by the United States Centers for Medicare and Medicaidtoneal dialysis than in hemodialysis patients, and transplanta-
tion in peritoneal dialysis patients is more frequently associated Services (CMS).
with early, but not late, graft failure. Delayed graft function was
less common in peritoneal dialysis patients but this potential
benefit appears to be offset by other factors which are associated METHODS
with early graft loss. Additional studies are needed to determine
Patient populationwhat factors may help understand this early risk of graft failure.
We included Medicare beneficiaries who (1) were 18
years old or older, (2) first started therapy for ESRDKey words: kidney transplantation, delayed graft function, allograft
survival, graft thrombosis. between 1995 and 1998, and (3) had been on the same
dialysis modality (hemodialysis or peritoneal dialysis)Received for publication February 22, 2002
for at least 60 days on day 90 of ESRD therapy [N and in revised form April 19, 2002
Accepted for publication May 8, 2002 252,402; hemodialysis  219,240 (87%); and peritoneal
dialysis  33,162 (13%)]. In our study of the effects of 2002 by the International Society of Nephrology
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dialysis modality on outcomes after kidney transplanta- including death, and return to dialysis or re-transplant
tion, we included those patients described above who (death-censored graft failure). Models were adjusted for
received a kidney-only transplant and had no prior his- dialysis exposure time, dialysis modality switch (whether
tory of other organ transplantation (N  22,776). a patient had switched modalities prior to transplanta-
tion), the year of transplantation, gender, race, age at time
Analytical methods of transplantation, Hispanic ethnicity, body size (BSA),
To determine the relative likelihood of peritoneal dial- obesity (BMI of 30 kg/m2 or more), baseline GFR, base-
ysis vs. hemodialysis patients to receive a kidney trans- line co-morbidity, education level, ability to work, human
plant, we used Cox proportional hazards analyses with lymphocyte antigens (HLA) mismatches, donor type, do-
kidney transplantation occurring before November 30, nor gender, donor age, donor race, panel reactive antibody
2000, as the end point. In two separate analyses we used (PRA), and cold ischemia time. Due to non-proportion-
both “intent-to-treat” based on dialysis modality on day ality of the hazards over time, additional Cox models
90, and “on treatment” with patients censored at a change were run on outcomes in the first 3 months post-transplant
in dialysis modality (change of at least 60 days) or if lost and conditional graft loss following the first 3 months. All
to follow-up. For both of these analyses, patients were analyses used SAS version 8.2 (Cary, NC, USA).
censored at death. These analyses were adjusted for age,
gender, race, Hispanic ethnicity, year of ESRD initiation,
body size measured as body surface area (BSA) calcu- RESULTS
lated from height and weight [15], obesity defined as Likelihood of transplantation
body mass index (BMI) greater than 29 kg/m2, estimated
During the follow-up period, a greater proportion ofbaseline glomerular filtration rate (GFR) at dialysis initi-
peritoneal dialysis vs. hemodialysis patients received aation (as calculated from serum creatinine, age, gender,
kidney transplant (Fig. 1). By 1, 3, and 5 years afterand race), diabetes as primary cause of renal failure,
starting dialysis for ESRD, the proportions of peritonealability to work, and baseline co-morbidities. Baseline
dialysis and hemodialysis patients receiving a kidneyco-morbidities were determined from the CMS Medical
transplant (by Kaplan-Meier analysis) were 9.2% (95%Evidence Form (Form 2728, End-Stage Renal Disease
CI  8.8 to 9.5%) vs. 3.8% (3.7 to 3.9%), 23.6% (23.0Medical Evidence Report Medicare Entitlement and/or
to 24.1%) vs. 10.9% (10.7 to 11.0%), and 31.7% (30.9Patient Registration). Co-morbidities included cardio-
to 32.6%) vs. 15.7% (15.5-16.0%), respectively. Simi-vascular disease (congestive heart failure, ischemic heart
disease, myocardial infarction, cardiac arrest, cardiac larly, in unadjusted Cox proportional hazards analysis,
dysrhythmia, and pericarditis), peripheral vascular dis- the relative likelihood of receiving a kidney transplant
ease (PVD), and hypertension. In the end, both the “in- was 2.34 (2.28 to 2.41, P  0.0001) times greater for
tent-to-treat” and “on treatment” analyses gave similar peritoneal dialysis than for hemodialysis patients. How-
results, and therefore only the “intent-to-treat” results ever, most of this difference can be explained by differ-
are presented. ences in the patients selected for peritoneal dialysis and
To determine the effect of pre-transplant dialysis mod- hemodialysis. Indeed, after adjustments were made for
ality on graft survival, three different approaches were differences in peritoneal dialysis and hemodialysis pa-
used: (1) the dialysis modality was determined on day tients, the relative likelihood of receiving a kidney trans-
90 of ESRD care and patients were assumed to be on plant was only 1.39 (1.35 to 1.43, P  0.0001) times
this modality until the time of transplantation (similar greater for peritoneal dialysis than for hemodialysis pa-
to intent-to-treat); (2) for patients switching modality tients (Table 1).
more the 60 days prior to transplantation and for a period
The difference in the likelihood of transplantation be-
of no less than 60 days, the new modality was taken as
tween peritoneal dialysis and hemodialysis patients doesthe pre-transplant dialysis modality; and (3) the pre-
not appear to be a result of differences in the likelihoodtransplant dialysis modality was determined from the
of making it to the waiting list for cadaveric renal trans-United Network for Organ Sharing (UNOS) Transplant
plantation. In this population, 87% of hemodialysis pa-Recipient Registration Form at the time of transplant.
tients were listed and 86% of peritoneal dialysis patientsIn the event this information was missing from the UNOS
were listed (2 P  0.4669). When only considering pa-form, the last known modality based on Medicare data
tients who received a cadaveric transplant, 99.8% of bothwas used. In the end, the results did not differ signifi-
hemodialysis and peritoneal dialysis patients had beencantly between these three approaches, and therefore
listed (2 P  0.8018). Similarly, for patients who wentonly the results from the third approach are presented.
on to receive a living donor transplant, 59% of bothSeparate Cox proportional hazards analyses were used
hemodialysis and peritoneal dialysis patients had beento assess the relative risk of pre-transplant peritoneal
dialysis vs. hemodialysis on patient survival, graft failure, listed (2 P  0.9877).
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Fig. 1. The percentages of new hemodialysis
(HD, solid line) and peritoneal dialysis (PD,
dashed line) patients who received a kidney
transplant by Kaplan-Meier analysis. Patients
shown here were analyzed by intention-to-
treat, where a change in dialysis modality was
ignored.
Table 1. Characteristics of peritoneal and hemodialysis patients that are associated with the relative likelihood of kidney transplantation
Percent with characteristic
Likelihood of transplantation
Among PD Among HD
Characteristic patients % patients % RR (95% CI) P value
PD vs. HD — — 1.39 (1.35–1.43) 0.0001
Female gender 46 47 0.85 (0.82–0.87) 0.0001
Age years
18 to 19 5 3 Reference —
30 to 44 35 52 0.65 (0.63–0.68) 0.0001
45 to 64 41 34 0.32 (0.31–0.33) 0.0001
65 18 11 0.03 (0.03–0.03) 0.0001
Race
Caucasian 65 52 Reference —
African American 21 32 0.34 (0.33–0.35) 0.0001
Other 14 15 0.56 (0.53–0.60) 0.0001
Hispanic ethnicity 9 11 1.03 (0.96–1.10) 0.4133
ESRD from diabetes 45 44 0.83 (0.81–0.86) 0.0001
Year of ESRD
1995 28 22 Reference —
1996 27 24 0.94 (0.90–0.97) 0.0006
1997 24 26 0.89 (0.85–0.92) 0.0001
1998 21 28 0.75 (0.72–0.79) 0.0001
Body Size (BSA)
Small (1.7 m2) 26 30 0.92 (0.88–0.95) 0.0001
Medium (1.7 to 1.9 m2) 43 41 Reference —
Large (1.9 m2) 31 29 1.08 (1.04–1.12) 0.0001
Obese (BMI 29 kg/m2) 18 20 0.68 (0.65–0.71) 0.0001
Baseline GFR mL/min
Low (6.1) 27 28 1.04 (1.01–1.07) 0.0215
Intermediate (6.1 to 8.7) 46 43 Reference —
High (8.7) 27 28 0.81 (0.78–0.84) 0.0001
Ability to work 49 48 1.66 (1.61–1.70) 0.0001
Co-morbidities
CVD 32 41 0.60 (0.58–0.63) 0.0001
PVD 11 13 0.61 (0.57–0.65) 0.0001
Hypertension 64 65 1.15 (1.12–1.19) 0.0001
Shown are the percent of pre-transplant PD (column 2, N  33,162) and HD (column 3, N  219,240) patients with characteristics in column 1, and the relative
likelihood of transplantation (columns 4 and 5). Abbreviations are: PD, peritoneal dialysis; HD, hemodialysis; RR, relative risk; CI, confidence interval; ESRD, end-
stage renal disease; BMI, body mass index; GFR, glomerular filtration rate; CVD, cardiovascular disease; PVD, peripheral vascular disease.
Transplant outcomes vs. hemodialysis (Fig. 2A), death-censored graft failure
was more frequent for peritoneal dialysis vs. hemodialy-Pre-transplant dialysis modality was associated with
sis patients (Fig. 2C), and there was no difference indifferences in outcomes after transplantation. There
overall graft failure in patients treated with peritonealwere 5621 (25%) patients on peritoneal dialysis and
dialysis vs. hemodialysis (Fig. 2B). However, using a Cox17,155 (75%) patients on hemodialysis prior to trans-
proportional hazards model to adjust for multiple riskplantation. In unadjusted (Kaplan-Meier) analysis, mor-
tality was less for those treated with peritoneal dialysis factors, peritoneal dialysis patients had similar rates of
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Fig. 2. Unadjusted (Kaplan-Meier) outcomes
comparing transplant recipients treated with
either peritoneal dialysis (PD, gray line) or
hemodialysis (HD, black line) pre-transplant.
Shown are mortality (A), graft failure due to
death, return to dialysis or re-transplantation
(B), or death-censored graft failure due to
dialysis or re-transplantation (C ). Log rank,
P  0.001; Wilcoxon, P  0.0002.
death and graft failure, but a 15% increased risk of death- plant. Data on the cause of graft failure were available
for only 1030 (33%) of hemodialysis patients and 401censored graft failure (Table 2).
Most of the risk attributable to pre-transplant dialysis (38%) of peritoneal dialysis patients on the UNOS trans-
plant recipient and follow-up forms. Of all of the causesmodality was manifest in the first 3 months following
transplantation (Fig. 2 B and C). In Cox proportional examined, only graft thrombosis was more frequent in
peritoneal dialysis vs. hemodialysis patients [odds ratiohazards analyses adjusted for multiple risk factors, but
1.59 (1.08 to 2.36), P  0.0192, Table 4].restricted to the first 3 months of follow-up, peritoneal
dialysis was clearly associated with a higher risk for graft
Delayed graft functionfailure and death-censored graft failure, but not mortal-
ity (Table 3). On the other hand, in adjusted Cox analyses We used logistic regression analysis to examine the
associated role of dialysis modality on the incidence ofthat included only patients whose grafts functioned for
at least 3 months, there was little effect of dialysis mod- delayed graft function (DGF), defined by the need for
dialysis during the first week after transplantation.ality on outcomes, emphasizing that the increased risk
in the peritoneal dialysis population occurs early in the Among hemodialysis patients, 16% of patients had DGF,
while only 12% of peritoneal dialysis patients had DGF.post-transplant period (Table 3).
The cause of graft failure was investigated for patients Pre-transplant peritoneal dialysis was associated with a
lower risk for DGF, with the odds ratio (peritoneal dial-whose grafts failed within the first 3 months post-trans-
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Table 2. Effects of pre-transplant dialysis modality and other factors on outcomes after kidney transplantation
Relative risk (95% CI)
Death-censored
Characteristics Graft failure graft failure Death
PD vs. HD 1.05 (0.97–1.13) 1.15 (1.04–1.26)a 0.95 (0.85–1.06)
Dialysis duration months 1.00 (0.99–1.00) 0.98 (0.98–0.99)c 1.02 (1.01–1.02)c
Changed dialysis modality 1.02 (0.90–1.14) 1.00 (0.85–1.17) 1.06 (0.90–1.24)
Transplant era
1995–1996 Reference Reference Reference
1997–1998 0.68 (0.63–0.74)c 0.56 (0.50–0.62)c 0.86 (0.76–0.98)a
1999–2000 0.82 (0.73–0.93)a 0.83 (0.72–0.97)a 0.78 (0.64–0.94)a
Female (vs. male) 1.08 (1.00–1.16)a 1.10 (1.00–1.21) 1.06 (0.95–1.17)
Age years
18 to 29 Reference Reference Reference
30 to 44 0.90 (0.80–1.01) 0.82 (0.72–0.93)a 1.39 (1.09–1.77)a
45 to 64 1.11 (1.00–1.24) 0.73 (0.64–0.83)c 2.87 (2.28–3.60)c
65 1.51 (1.32–1.74)c 0.64 (0.53–0.78)c 5.14 (4.02–6.58)c
Race
Caucasian Reference Reference Reference
African American 1.03 (0.95–1.12) 1.19 (1.06–1.33)a 0.84 (0.75–0.95)a
Other 0.73 (0.62–0.86) 0.76 (0.61–0.95)a 0.66 (0.52–0.84)b
Hispanic ethnicity 1.04 (0.86–1.25) 1.15 (0.90–1.48) 0.93 (0.70–1.22)
ESRD from diabetes 1.13 (1.05–1.22)b 0.80 (0.72–0.89)c 1.65 (1.50–1.82)c
Body size (BSA)
Small (1.7 m2) 1.03 (0.94–1.13) 0.99 (0.87–1.12) 1.11 (0.97–1.26)
Medium (1.7 to 1.9 m2) Reference Reference Reference
Large (1.9 m2) 1.01 (0.93–1.10) 1.08 (0.96–1.21) 0.91 (0.80–1.03)
Obese (BMI 29 kg/m2) 1.00 (0.91–1.10) 0.95 (0.84–1.09) 1.06 (0.93–1.22)
Baseline GFR mL/min
Low (6.1) 0.94 (0.88–1.02) 0.97 (0.88–1.07) 0.90 (0.80–1.00)
Intermediate (6.1 to 8.7) Reference Reference Reference
High (8.7) 1.13 (1.03–1.25)a 1.14 (1.00–1.30) 1.14 (1.00–1.31)a
Co-morbidities
CVD 1.11 (1.02–1.21)a 0.90 (0.78–1.03) 1.32 (1.17–1.48)c
PVD 1.21 (1.04–1.41)a 1.06 (0.83–1.36) 1.31 (1.09–1.58)a
Hypertension 0.94 (0.87–1.01) 0.92 (0.84–1.01) 0.95 (0.86–1.06)
HLA mismatches
0 0.85 (0.76–0.95)a 0.89 (0.76–1.03) 0.82 (0.70–0.96)a
1 0.98 (0.83–1.15) 0.95 (0.76–1.18) 1.03 (0.83–1.29)
2 0.91 (0.82–1.02) 0.98 (0.85–1.13) 0.89 (0.76–1.04)
3 Reference Reference Reference
4 1.10 (0.99–1.21) 1.19 (1.04–1.36)a 0.98 (0.85–1.13)
5 1.13 (1.01–1.26)a 1.16 (1.00–1.34)a 1.10 (0.94–1.28)
6 1.27 (1.10–1.46)b 1.33 (1.10–1.60)a 1.23 (1.02–1.50)a
Living donor 0.88 (0.79–0.98)a 0.98 (0.86–1.13) 0.71 (0.60–0.83)c
Female donor 1.08 (1.01–1.15)a 1.09 (1.00–1.19)a 1.03 (0.94–1.13)
Donor age years
0 to 17 0.96 (0.84–1.10) 1.07 (0.90–1.27) 0.91 (0.75–1.09)
18 to 29 Reference Reference Reference
30 to 44 1.10 (1.00–1.22) 1.12 (0.98–1.29) 1.09 (0.94–1.26)
45 to 64 1.41 (1.28–1.56)c 1.51 (1.32–1.72)c 1.37 (1.19–1.57)c
65 1.99 (1.69–2.34)c 2.43 (1.95–3.04)c 1.84 (1.49–2.28)c
Donor race
Caucasian Reference Reference Reference
African American 1.24 (1.11–1.37)c 1.21 (1.05–1.39)a 1.30 (1.11–1.51)b
Other 0.96 (0.83–1.10) 0.95 (0.79–1.14) 0.96 (0.78–1.18)
PRA 50% 1.20 (0.97–1.48) 1.32 (1.01–1.74)a 1.13 (0.84–1.53)
Cold ischemia time hours
0 Reference Reference Reference
1 to 12 1.20 (1.03–1.40)a 1.31 (1.07–1.61)a 0.96 (0.76–1.20)
13 to 24 1.43 (1.20–1.71)c 1.62 (1.29–2.05)c 1.05 (0.81–1.36)
25 1.43 (1.19–1.71)b 1.73 (1.36–2.19)c 1.02 (0.79–1.33)
College educated 0.88 (0.80–0.97)a 0.89 (0.78–1.01) 0.86 (0.75–0.99)a
Ability to work 0.92 (0.85–0.99)a 0.98 (0.89–1.09) 0.80 (0.71–0.89)c
Abbreviations are: PD, peritoneal dialysis; HD, hemodialysis; ESRD, end-stage renal disease; BSA, body surface area; BMI, body mass index; GFR, glomerular
filtration rate; CVD, cardiovascular disease; PVD, peripheral vascular disease; HLA, human leukocyte antigen; PRA, panel reactive antibody.
a P  0.05; b P  0.001; c P  0.0001
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Table 3. Effects of pre-transplant dialysis modality on outcomes early vs. late after kidney transplantation
Relative risk (95% CI) PD:HD
Death-censored
Post-transplant period Graft failure graft failure Death
During the first 3 months 1.23 (1.09–1.39)a 1.33 (1.16–1.53)b 1.03 (0.81–1.30)
Beyond the first 3 months 0.96 (0.87–1.05) 1.02 (0.89–1.16) 0.91 (0.80–1.04)
Results of Cox proportional hazards analyses (adjusted for covariates in Table 2) during the first 3 months after transplantation and beyond the first 3 months
after transplantation (among those patients who survived with functioning grafts for at least 3 months).
a P  0.001; b P  0.0001
Table 4. Causes of graft failure (primary or contributing) for patients whose graft failed within the first 3 monthsa
Percent with characteristic
Cause Among PD patients (%, N ) Among HD patients (%, N ) P valueb
Hyperacute rejectionc 3 (3/95) 4 (7/195) 1.0000
Surgical complicationsc 3 (3/95) 6 (11/195) 0.5602
Acute rejectiond 27 (42/156) 27 (95/349) 0.9446
Primary failured 13 (21/156) 15 (52/349) 0.6711
Graft thrombosisd 41 (64/156) 30 (106/349) 0.0192
Infectiond 8 (12/156) 10 (34/349) 0.4595
Urological complicationsd 2 (3/156) 2 (7/349) 1.0000
Recurrent diseased 3 (4/156) 2 (6/349) 0.5071
Otherd 15 (23/156) 19 (66/349) 0.2561
a Patients may have more than one cause of graft failure
b P value from Fisher’s exact test (when fewer than five expected events) or Chi-square test
c For patients whose graft failed immediately
d For patients whose graft failed immediately or after discharge
ysis:hemodialysis) for DGF being 0.74 (0.67 to 0.81, P  plant compared to hemodialysis patients. While many
of the factors associated with increased transplant utiliza-0.0001) after adjustment for multiple covariates. For pa-
tients whose graft survived at least 7 days, DGF was tion may be more represented in the peritoneal dialysis
population, the difference in transplant utilization per-associated with a 2.8 (2.2 to 3.6, P 0.0001) times greater
risk of death, a 2.9 (2.6 to 3.4, P  0.0001) times greater sisted after adjusting the analysis for differences in pa-
tient characteristics (Table 1). There may be a perceptionrisk of graft failure, and a 2.9 (2.5 to 3.5, P 0.0001) times
greater risk of death-censored graft failure, regardless of among patients and their physicians that peritoneal dial-
ysis is the dialysis treatment modality of choice for trans-pre-transplant dialytic modality. The observed increased
plant candidates [3, 17]. If placement of a peritonealrisk of graft failure and death-censored graft failure in
dialysis catheter is thought to cause less morbidity andthe peritoneal dialysis population in the first 3 months
mortality than placement of a hemodialysis access, thenpost-transplant is present despite the apparent beneficial
peritoneal dialysis may be selected more often than he-effects of a lower incidence of DGF in the peritoneal
modialysis when it is perceived to be a better short-termdialysis population.
bridge to kidney transplantation. On the other hand, if
there is a perception that hemodialysis offers better long-
DISCUSSION term dialysis treatment, then patients less likely to un-
In our analysis, peritoneal patients were approxi- dergo transplantation may be selected for hemodialysis
mately 50% more likely to undergo kidney transplanta- more often than peritoneal dialysis. In any case, it is
tion compared to hemodialysis patients. Few others have plausible that the observed difference in the likelihood
compared the rates of transplantation for peritoneal and for peritoneal dialysis vs. hemodialysis patients to receive
hemodialysis patients. More than a decade ago, Held et a kidney transplant could be due to a selection bias,
al found that the rate of transplantation among 3393 whereby transplant candidates were more likely to be
children was similar, albeit slightly higher, for peritoneal placed on peritoneal dialysis than hemodialysis.
dialysis vs. hemodialysis patients [16]. These investiga- An important and surprising finding in this study is
tors did not examine the rates of transplantation among the higher rate of early graft failure in peritoneal dialysis
adult peritoneal dialysis and hemodialysis patients. compared to hemodialysis patients even after adjusting
We cannot discern from our analysis why peritoneal for multiple patient characteristics that may also influ-
ence outcomes. Most other studies have reported thatdialysis patients were more likely to receive a kidney trans-
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pre-transplant dialysis modality has no effect on patient vs. hemodialysis patients is the possibility that residual
native kidney function is better preserved in peritonealor graft survival [2, 9–14]. Similarly, most investigators
found no difference in the rates of acute rejection in dialysis than in hemodialysis [22–24]. The reduced early
graft survival associated with peritoneal dialysis com-peritoneal dialysis vs. hemodialysis [2, 4, 9, 13]. However,
Vanholder et al reported a greater number of peritoneal pared to hemodialysis is all the more remarkable given the
lower incidence of DGF in peritoneal dialysis patients.dialysis patients developed acute rejection after trans-
plantation compared to hemodialysis [3]. Most of these We attempted to determine which dialysis modality
patients with DGF were treated with by searching Medi-studies were smaller than the current investigation, and
the investigators did not separately examine the effects care Part B claims within 1 month of the transplant date.
In this study population, DGF was indicated for 3533of dialysis modality on short-term and long-term graft
survival. This is an important issue since the hazard func- patients. Claims could only be reliably searched for 2626
of these patients for whom Medicare appeared to betions are not proportional over time. As a result, it is
not surprising that others did not find the association the primary payer. Of these patients, we were able to
determine which modality patients were treated withbetween dialysis modality and early graft failure that we
report here. for 1925 (73%) patients. For the 351 peritoneal dialysis
patients, 166 (47%) were treated with peritoneal dialysisWe could not determine how pre-transplant dialysis
modality influenced early post-transplant graft failure. following transplantation. In the 1574 hemodialysis pa-
tients, 1551 (99%) were treated with hemodialysis fol-The result seems unlikely to be explained by a higher
rate of infection in peritoneal dialysis patients, since this lowing transplantation. These differences suggest it is
possible that the effects of pre-transplant dialysis mod-would be expected to have a greater effect on mortality
than death-censored graft failure. In addition, previous ality on early graft failure may have been influenced by
the effects of dialysis modality during DGF. Few studiesstudies comparing the rates of post-transplant infections
between peritoneal dialysis and hemodialysis patients have examined the effects of dialysis modality on the
have produced conflicting results. Passalacqua et al found pharmacokinetics of immunosuppressive agents. In a re-
a higher incidence of infection in the first 30 days post- cent study, the active metabolite of mycophenolate mo-
transplant, and this higher rate of infection was associ- fetil, mycophenolic acid, was found to be readily removed
ated with rejection and longer hospital stays [18]. Binaut by peritoneal dialysis [25]. Thus, it is possible that rejec-
et al reported no overall difference in bacterial infec- tion rates in patients with DGF could be indirectly influ-
tions, but a higher rate of sepsis was seen in peritoneal enced by pre-transplant dialysis modality, if levels of
dialysis vs. hemodialysis patients [2]. Others have found immunosuppressive medications are altered. More work
no difference in the rate of post-transplant infections in in this area is needed to determine the possible risk factors
peritoneal vs. hemodialysis patients [3, 19]. Still others and the associated complications post-transplant that
have reported that hemodialysis patients have a higher may be amenable to interventions.
rate of infections after transplantation [20]. Thus, it
seems unlikely that a higher rate of infection in perito-
CONCLUSIONneal dialysis patients could explain the association be-
In summary, this analysis demonstrated that the ratetween dialysis modality and early graft failure.
of transplantation is higher in patients treated with peri-In a subset of about one third of patients with data
toneal dialysis compared to patients treated with hemo-on the cause of graft failure, graft thrombosis was more
dialysis, and this difference could not be entirely explainedcommon in peritoneal dialysis vs. hemodialysis patients
by differences in the two patient populations. Interest-(Table 4). Graft thrombosis has also been reported by
ingly, the rate of early, but not late, graft failure was higherothers to be more common in peritoneal dialysis vs.
in patients treated with peritoneal dialysis compared tohemodialysis patients [6–9]. Indeed, we found only one
hemodialysis prior to transplantation. Although we can-study that examined the incidence of graft thrombosis
not determine the cause of this associated higher rateand failed to find a difference in peritoneal dialysis vs.
of graft failure, an analysis of a subset of patients withhemodialysis patients [21]. Thus, it is likely that early
data on the cause of graft failure suggested that a highergraft thrombosis contributed to the higher rate of early
rate of graft thrombosis might have contributed. Addi-graft failure associated with pre-transplant peritoneal
tional studies are needed to better understand the slightlydialysis. However, our results should be interpreted cau-
higher rate of early graft failure in the peritoneal dialysistiously, given that the large proportion of missing data
population.on the cause of graft failure could bias the results.
We found that DGF is less common in patients treated
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